Novolin 70-30 Innolet Side Effects Center

Last updated on RxList: 1/18/2023
Novolin 70-30 Innolet Side Effects Center

What Is Novolin 70-30 Innolet?

Novolin 70/30 InnoLet [70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)] is a form of insulin, a hormone produced in the body, used to treat diabetes. Novolin 70/30 InnoLet is available over-the-counter.

What Are Side Effects of Novolin 70-30 Innolet?

Novolin 70-30 Innolet may cause serious side effects including:

  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • muscle cramps,
  • weakness,
  • irregular heartbeat,
  • sudden sweating,
  • shaking,
  • fast heartbeat,
  • hunger,
  • blurred vision,
  • dizziness,
  • tinging hands or feet,
  • thirst,
  • increased urination,
  • confusion,
  • drowsiness,
  • flushing,
  • rapid breathing,
  • fruity breath odor, and
  • severe dizziness

Get medical help right away, if you have any of the symptoms listed above.

Common side effects of Novolin 70/30 InnoLet include:

  • localized reactions such as red, swollen and itchy skin where the insulin has been injected.

Novolin 70/30 InnoLet can cause low blood sugar (hypoglycemia). Symptoms of low blood sugar include sudden sweating, shaking, fast heartbeat, hunger, blurred vision, dizziness, or tingling hands/feet. Tell your doctor if you have rare symptoms of insulin allergy including:

  • skin rash over the body,
  • shortness of breath,
  • fast pulse,
  • sweating, and
  • a drop in blood pressure.

Seek medical care or call 911 at once if you have the following serious side effects:

  • Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
  • Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; and sudden dizziness, lightheadedness, or passing out;
  • Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors.

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

Dosage for Novolin 70-30 Innolet

Novolin 70/30 is a mixture of 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin). The concentration of this product is 100 units of insulin per milliliter.

What Drugs, Substances, or Supplements Interact with Novolin 70-30 Innolet?

Novolin 70/30 InnoLet may interact with other drugs. Tell your doctor all medications and supplements you use.

Novolin 70-30 Innolet During Pregnancy or Breastfeeding

Consult your doctor to discuss the best way to manage your diabetes while you are pregnant or breastfeeding.

Additional Information

Our Novolin 70/30 [70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection (recombinant DNA origin)] Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

QUESTION

Diabetes is defined best as... See Answer
Novolin 70-30 Innolet Consumer Information

Get emergency medical help if you have signs of insulin allergy: redness or swelling where an injection was given, itchy skin rash over the entire body, trouble breathing, chest tightness, feeling like you might pass out, or swelling in your tongue or throat.

Call your doctor at once if you have:

  • fluid retention--weight gain, swelling in your hands or feet, feeling short of breath; or
  • low potassium--leg cramps, constipation, irregular heartbeats, fluttering in your chest, increased thirst or urination, numbness or tingling, muscle weakness or limp feeling.

Common side effects may include:

  • low blood sugar;
  • weight gain, swelling in your hands or feet;
  • itching, mild skin rash; or
  • thickening or hollowing of the skin where you injected the medicine.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Diabetes: What Raises and Lowers Your Blood Sugar Level? See Slideshow
Novolin 70-30 Innolet Professional Information

SIDE EFFECTS

The following adverse reactions are also discussed elsewhere in the labeling:

  • Hypoglycemia [see WARNINGS AND PRECAUTIONS]
  • Medication Errors [see WARNINGS AND PRECAUTIONS]
  • Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]
  • Hypokalemia [see WARNINGS AND PRECAUTIONS]

Adverse Reactions From Clinical Studies Or Postmarketing Reports

The following additional adverse reactions have been identified during clinical studies or from postmarketing reports with use of NOVOLIN 70/30. Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.

Adverse Reactions Associated With Insulin Initiation And Glucose Control Intensification

Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. Over the long-term, improved glycemic control decreases the risk of diabetic retinopathy and neuropathy.

Hypersensitivity Reactions

Severe, life-threatening, generalized allergy, including anaphylaxis.

Hypoglycemia

Hypoglycemia is the most commonly observed adverse reaction in NOVOLIN 70/30.

Hypokalemia

NOVOLIN 70/30 can cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.

Injection Site Reactions

NOVOLIN 70/30 can cause local injection site reactions including redness, swelling, or itching at the site of injection. These reactions usually resolve in a few days to a few weeks, but in some occasions, may require discontinuation. Localized reactions and generalized myalgias have been reported with the use of metacresol, which is an excipient in NOVOLIN 70/30.

Lipodystrophy

Administration of insulin subcutaneously, including NOVOLIN 70/30, has resulted in lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) [see DOSAGE AND ADMINISTRATION] in some patients.

Localized Cutaneous Amyloidosis

Localized cutaneous amyloidosis at the injection site has occurred. Hyperglycemia has been reported with repeated insulin injections into areas of localized cutaneous amyloidosis; hypoglycemia has been reported with a sudden change to an unaffected injection site.

Medication Errors

Medication errors in which other insulins have been accidentally substituted for NOVOLIN 70/30 have been identified during postapproval use.

Peripheral Edema

Insulins, including NOVOLIN 70/30, may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.

Weight Gain

Weight gain can occur with insulins, including NOVOLIN 70/30, and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.

Immunogenicity

As with all therapeutic proteins, insulin administration may cause anti-insulin antibodies to form. The incidence of antibody formation with NOVOLIN 70/30 is unknown.

DRUG INTERACTIONS

Table 1: Clinically Significant Drug Interactions with NOVOLIN 70/30

Drugs that May Increase the Risk of Hypoglycemia
Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics
Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when NOVOLIN 70/30 is co-administered with these drugs.
Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLIN 70/30
Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.
Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when NOVOLIN 70/30 is co-administered with these drugs.
Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of NOVOLIN 70/30
Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.
Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when NOVOLIN 70/30 is co-administered with these drugs.
Drugs that May Blunt Signs and Symptoms of Hypoglycemia
Drugs: Beta-blockers, clonidine, guanethidine, and reserpine
Intervention: Increased frequency of glucose monitoring may be required when NOVOLIN 70/30 is co-administered with these drugs.

Read the entire FDA prescribing information for Novolin 70-30 Innolet (70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection)

Read More »

© Novolin 70-30 Innolet Patient Information is supplied by Cerner Multum, Inc. and Novolin 70-30 Innolet Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors